Washington Post reports:
The group — which is announcing its formation Monday, under the name Doctors for Cannabis Regulation (DFCR) — is endorsing the legalization of marijuana for adult recreational use, a break from the position of the American Medical Association, the largest organization of doctors in the country. DFCR argues that the prohibition and criminalization of marijuana use does more harm to the public than good. Citing hundreds of thousands of annual marijuana arrests, racial and economic disparities in marijuana enforcement, and the role of prohibition in keeping marijuana prices high and lucrative to violent drug dealers, the physicians say that creating a legal and regulated marijuana market is the best way to ensure public safety, combat the illicit drug trade and roll back the negative consequences of strict enforcement policies on disadvantaged communities.
The emergence of the group comes at a crucial moment in the national debate over marijuana legalization. More than 60 percent of the public now says that it supports marijuana legalization. Support for allowing medical use of marijuana with doctors' supervision is closer to 90 percent. Over 35 million Americans use marijuana recreationally each year, according to the latest federal statistics. Research organizations, medical groups and even many national lawmakers have called on federal authorities to revisit policies toward marijuana that have remained essentially unchanged for nearly 50 years.
Members of the organization’s leadership team include former U.S. Surgeon General Dr. Joycelyn Elders; integrative medicine pioneer Dr. Andrew Weil; Dr. H. Westley Clark, former director of the Center for Substance Abuse Treatment; Dr. Chris Beyrer, founder and director of the Johns Hopkins Center for Public Health and Human Rights; Dr. Lester Grinspoon, Associate Professor Emeritus of Psychiatry at Harvard Medical School; Dr. David Lewis, Professor Emeritus of Medicine and Community Health at Brown University; Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital; and Dr. David Nathan, a Distinguished Fellow of the American Psychiatric Association and Clinical Associate Professor of Psychiatry at Rutgers Robert Wood Johnson Medical School.